Inhibikase Therapeutics, Inc. · NASDAQ:IKT
Fairmount Funds Management LLC reported a 9.90% stake in Inhibikase Therapeutics, Inc. (Schedule 13G/A)
Event Dec 31, 2024 · Filed Feb 14, 2025
Fairmount Funds Management LLC reported a 9.90% stake in Inhibikase Therapeutics, Inc., 7,018,575 shares, as a passive investor on Dec 31, 2024. Filed Feb 14, 2025 (Schedule 13G/A).
- Stake
- 9.90%
- Shares
- 7,018,575
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 4 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Fairmount Funds Management LLC | 9.90% | 7,018,575 |
| Fairmount Healthcare Fund II L.P. | 9.90% | 7,018,575 |
| Peter Harwin | 9.90% | 7,018,575 |
| Tomas Kiselak | 9.90% | 7,018,575 |
Source
Related
- Inhibikase Therapeutics, Inc.
- Fairmount Funds Management LLC
- Inhibikase Therapeutics, Inc. shareholders
- Schedule 13G/A · Fairmount Funds Management LLC · Feb 17, 2026
- Schedule 13G/A · Perceptive Advisors LLC · Aug 14, 2026
- Schedule 13G/A · Nantahala Capital Management, LLC · Aug 14, 2026
- Schedule 13G/A · Sands Capital Life Sciences Pulse Fund II, L.P. · Aug 13, 2026
- Form 4 · Berman Dennis N · Jul 31, 2026
- Form 4 · RA Capital Healthcare Fund LP · Jul 31, 2026